RESPIGAM DIN 02232480
Status: Cancelled Pre Market
Holder: MEDIMMUNE LLC
Health Canada record
| Active ingredient(s) | RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) 50 MG |
|---|---|
| Dosage form | Liquid |
| Route | Intravenous |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J06BA02 IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASC. ADM. |
| Original market date | |
| Current status date | 28-Aug-2017 |
| Source | Health Canada DPD |
Establishment licence of the holder
Medimmune UK Limited — licence , not currently licensed, last inspection rating C (2024-05-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02232478 | RESPIGAM | MEDIMMUNE LLC | Powder For Solution | RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) 1000 MG | Cancelled Pre Market |
| 02232479 | RESPIGAM | MEDIMMUNE LLC | Powder For Solution | RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN) 2500 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 4046 | 1997-08-20 | New Drug Submission (NDS) |